CAR T Yescarta among new approvals by Japanese regulator

Yescarta became the second approved CAR T therapy in Japan, joining a basket of new approvals by the country’s Ministry of Health, Labour and Welfare.

The therapy, developed by Gilead Sciences Inc. (NASDAQ:GILD) and partnered with Daiichi Sankyo Co. Ltd. (Tokyo:4568), followed Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) to market in Japan...